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Abstract
Background: Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. 
However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy. Therefore, 
characterization of cellular mechanisms involved in bortezomib resistance and development of effective strategies to 
overcome this resistance represent important steps in the advancement of bortezomib-mediated cancer therapy.
Results: The present study reports the development of I-45-BTZ-R, a bortezomib-resistant cell line, from the 
bortezomib-sensitive mesothelioma cell line I-45. I-45-BTZ-R cells showed no cross-resistance to the chemotherapeutic 
drugs cisplatin, 5-fluorouracil, and doxorubicin. Moreover, the bortezomib-adapted I-45-BTZ-R cells had decreased 
growth kinemics and did not over express proteasome subunit β5 (PSMB5) as compared to parental I-45 cells. I-45-BTZ-
R cells and parental I-45 cells showed similar inhibition of proteasome activity, but I-45-BTZ-R cells exhibited much less 
accumulation of ubiquitinated proteins following exposure to 40 nm bortezomib. Further studies revealed that 
relatively low doses of bortezomib did not induce an unfolded protein response (UPR) in the bortezomib-adapted cells, 
while higher doses induced UPR with concomitant cell death, as evidenced by higher expression of the mitochondrial 
chaperone protein Bip and the endoplasmic reticulum (ER) stress-related pro-apoptotic protein CHOP. In addition, 
bortezomib exposure did not induce the accumulation of the pro-apoptotic proteins p53, Mcl-1S, and noxa in the 
bortezomib-adapted cells.
Conclusion: These results suggest that UPR evasion, together with reduced pro-apoptotic gene induction, accounts 
for bortezomib resistance in the bortezomib-adapted mesothelioma cell line I-45-BTZ-R.
Background
The 26S proteasome is a multi-subunit enzymatic com-
plex composed of a barrel-shaped 20S core region with
catalytic activity adjacent to a 19S regulatory complex [1].
Recent investigations have revealed that the ubiquitin-
proteasome pathway plays a key role in regulating the
homeostasis of cellular proteins involved in cell cycle reg-
ulation, cell survival, and apoptosis. Therapeutic target-
ing of the proteasome pathway with the specific inhibitor
bortezomib has been successful in selectively inducing
apoptosis in mesothelioma and a variety of other human
cancer cells, with tolerable toxicity to normal cells and
tissues [2-4]. Importantly, bortezomib has received US
FDA approval for the treatment of patients with multiple
myeloma (MM) and mantle cell lymphoma [5].
However, cancer cell resistance to bortezomib-medi-
ated apoptosis may limit the successful application of
bortezomib as a cancer therapeutic agent. Although bort-
ezomib shows much stronger anti-tumor activity in MM
than in solid tumors, approximately 50% of MMs do not
respond to this medication [6,7]. Moreover, many
patients with MM who initially responded to bortezomib
ultimately relapse with bortezomib-refractory disease [8],
suggesting that even in the cancer exhibiting the best
treatment response, bortezomib resistance remains a sig-
nificant obstacle to treatment efficacy.
Bortezomib (PS-341, or Velcade) is a dipeptidyl boronic
acid that reversely inhibits 20S proteasome activity. In
MM, the transcriptional regulatory protein nuclear factor
κB (NFκB) has been proposed as a major target of borte-
zomib [4,9,10]. Bortezomib blocks the degradation of IκB,
a cytoplasmic NFκB inhibitory protein, effectively reduc-
ing NFκB translocation from the cytoplasm to the
nucleus and blocking its transcriptional regulatory activ-
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Page 2 of 9ity. Given the established roles of NFκB in angiogenesis,
cell invasion, oncogenesis, proliferation, and inhibition of
apoptosis, inhibition of this important transcription fac-
tor is widely regarded as an attractive strategy of cancer
therapy and a primary mechanism of bortezomib anti-
tumor activity in MM cells [4,9,10]. Moreover, as a pro-
teasome inhibitor, bortezomib is able to overcome
chemoresistance or induce chemosensitization by inhib-
iting the NFκB functions that are typically activated by
conventional chemotherapeutic agents [9,10]. Beyond
NFκB inhibition, bortezomib also induces the intracellu-
lar unfolded protein response (UPR) [11] and stabilizes
the expression of the proapoptotic genes p53 [12], Bim
[13], or noxa [14], indirectly contributing to bortezomib
anti-tumor activity.
Although progress has made in defining bortezomib
mechanisms of action, mechanisms of bortezomib resis-
tance in cancer are not well understood. In one early
study, heat shock protein 27 (HSP27) was shown to play
an important role in bortezomib resistance [15]. Recently,
evidence was reported supporting a relationship between
proteasome subunit β5 (PSMB5) expression and borte-
zomib resistance. Bortezomib is a reversible inhibitor that
primarily targets PSMB5, which is responsible for the
chymotrypsin activity of the 26S proteasome. Several
studies focused on acute myeloid leukemia, lymphoma,
and MM have shown that a series of bortezomib-adapted
cell lines developed from the above malignancies exhibit
higher PSMB5 expression at the both RNA and protein
levels than the respective parental bortezomib-sensitive
cells [16-19]. Further investigation demonstrated that
inhibition of PSMB5 expression partially restored borte-
zomib sensitivity in resistant cells [18].
In the present study, a novel bortezomib resistant cell
line was developed from the mesothelioma cell line I-45.
Our results suggest that UPR evasion together with
reduced pro-apoptotic gene induction accounted for
bortezomib resistance in this new bortezomib-adapted
mesothelioma cell line.
Results
Development of the bortezomib-adapted mesothelioma 
cell line I-45-BTZ-R
To determine whether prolonged exposure of the meso-
thelioma cell line I-45 to bortezomib would select for
cells resistant to bortezomib treatment, I-45 cells were
exposed to 12 nM bortezomib (its IC50 concentration).
The RPMI-1640 cell culture medium was changed every
three days and fresh bortezomib was added at the same
time. After one month of cell incubation at this concen-
tration, the selection concentration was increased to 15
nM. Extracellular concentrations of bortezomib were
increased in a step-wise fashion over a period of 6
months, culminating in a drug concentration of 40 nM.
Selection was halted at this dose, since 40 nM is already
higher than average plasma concentrations measured in
patients following administration of therapeutically effec-
tive does of bortezomib. The Bortezomib-adapted meso-
thelioma cell line I-45-BTZ-R showed consistent
resistance to bortezomib, as I-45-BTZ-R cells maintained
the same degree of resistance after two months of culture
in bortezomib-free medium. As is presented in Figure 1A,
three days after treatment with different concentrations
of bortezomib, I-45-BTZ-R cells showed much higher cell
viability than parental I-45 cells, with IC50 values of 185.5
± 0.3 nM and 12.1 ± 0.4 nM, respectively. Cleavage of cas-
pase-3 or PARP was used as an indicator of bortezomib-
induced apoptosis. As seen in Figure 1B, one, two, or
three days after cells of exposure to 40 nM bortezomib,
this agent induced caspase-3 and PARP cleavage in
parental I-45 cells, but not in I-45-BTZ-R cells. These
data indicated that I-45-BTZ-R cells do not undergo
apoptosis following bortezomib treatment. Cell cycle
analysis of treatment-induced sub-G1 cell populations
(Figure 1C) confirmed these results. As expected, borte-
zomib did not induce strong G2/M arrest in I-45-BTZ-R
cells as compared with parental I-45 cells (Figure 1C). 25
nM bortezomib treatment for 72 hours increased G2/M
population to 70.9% from 4% of the basal level in parental
I-45 cells. However, the same treatment even did not
change G2/M phase population in I-45-BTZ-R cells,
which remained 10.5% as compared to 10.1% of the basal
level. With increase in treatment doses, bortezomib
induced less G2/M arrest in I-45 cells, which may indi-
cate that more cells at G2/M phase went to apoptotic sub-
G1 phase.
To determine cell growth kinetics, the same numbers of
both cell types were maintained in culture for eight days.
Interestingly, I-45-BTZ-R cells exhibited significantly
reduced cell growth as compared to I-45 cells (p < 0.05 at
day 2; p < 0.01 at days 4, 6, and 8) (Figure 1D).
Proteasome subunit PSMB5 protein expression and 
chymotrypsin-like activity of in I-45-BTZ-R and I-45 cells
Several recent reports on acute myeloid leukemia, lym-
phoma, and MM described increased PSMB5 RNA and
protein expression in bortezomib-adapted cells, and inhi-
bition of PSMB5 expression partially restored bortezomib
sensitivity in resistant cells, indicating that PSMB5 over
expression is important for bortezomib resistance in can-
cer [16-19]. However, the present study did not detect a
difference in PSMB5 protein expression between the two
cell lines (Figure 2A). Moreover, expression of two other
proteasome subunits, β1 (PSMB1) and β2 (PSMB2),
which are responsible for caspase-like, or trypsin-like
activity, respectively, was also not altered in the resistant
cell line (Figure 2A).
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motrypsin-like activity, we also evaluated proteasome
chymotrypsin-like activity in parental and resistant cell
lines using a substrate fluorescence assay. Although basal
chymotrypsin-like activity was reduced approximately
30% in I-45-BTZ-R cells as compared to I-45 cells, both
cell lines maintained approximately 25 to 40% of their
original proteasome activity following bortezomib treat-
ment (Figure 2B). These data indicated that chy-
motrypsin-like activity can be inhibited by bortezomib
not only in parental I-45 cells, but also in I-45-BTZ-R
cells, and that the mechanisms underlying I-45-BTZ-R
cell resistance to bortezomib may be independent of pro-
teasome activity.
Characteristic features of proteasome inhibition
include the accumulation of ubiquitinated proteins,
which can induce ER stress and UPR, and stabilization of
pro-apoptotic genes, leading to mitochondrial membrane
potential changes and apoptosis [11]. To this end, we
evaluated the expression of ubiquitinated proteins in both
cell lines following bortezomib treatment. As is shown in
Figure 2C, basal levels of ubiquitinated proteins were
similar in both of the cell lines. However, the concentra-
tion of ubiquitinated proteins in I-45 cells increased
sharply 24 hours after exposure to 40 nM bortezomib,
with further increases observed after 48 or 72 hours of
drug exposure. Conversely, I-45-BTZ-R cells exhibited
lower accumulation of ubiquitinated proteins after 24
Figure 1 Characterization of the bortezomib-adapted cell line I-45-BTZ-R. A: I-45 and I-45-BTZ-R cells were treated with bortezomib (3.13 nM to 
400 nM) for 72 hours. Cell viability was determined after treatment using the XTT assay. Control cells were treated with PBS and their viability was set 
as 100%. Values are the mean ± SD of triplicate assays from two experiments. B: I-45 and I-45-BTZ-R cells were treated with 40 nM bortezomib for 24, 
48, or 72 hours. Caspase-3 and PARP activation (cleavage) were analyzed by Western blot analysis. C: I-45 and I-45-BTZ-R cells were treated with bort-
ezomib (25 nM to 200 nM) for 72 hours. Percentages of sub-G1 cells and cell cycle distribution were determined by flow cytometry analysis. Values 
are the mean ± SD of two experiments. D: I-45 and I-45-BTZ-R cells were seeded into 20 cm cell culture dishes (1 × 106 cells per dish). At days 2, 4, 6, 
or 8, the cells were trypsinized and stained with trypan blue. Viable cells were counted under a microscope using a hemocytometer. Values are the 
mean ± SD of three experiments.
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Page 4 of 9hours of bortezomib exposure, and the concentration of
ubiquitinated proteins returned to the basal level follow-
ing 48 or 72 hours.
Since I-45-BTZ-R cells survived yet maintained the
same low proteasome activity and showed much less
accumulation of ubiquitinated proteins as did I-45 cells in
response to toxic doses of bortezomib, we hypothesized
that alternate cellular protease pathways might have
become activated, essentially compensating for reduced
26S proteasome activity in I-45-BTZ-R cells and reducing
bortezomib toxicity. One candidate protease was tripepti-
dyl peptidase II (TPPII), which plays a critical role in
cleaving proteasomal-produced peptides into tripeptides
prior to further degradation by other peptidases. TPPII
upregulation has been reported in some lymphoma cells
resistant to the proteasome inhibitor tri-leucine-vinyl-
sulphone (NLVS), and inhibition of TPPII function using
the specific inhibitor AAF-CMK either directly induces
apoptosis or indirectly induces NLVS-mediated cell death
[20,21]. In the present study, TPPII expression was not
evident in either I-45 or I-45-BTZ-R cells by Western blot
analysis (data not shown). Moreover, treatment with
AAF-CMK at 5, 10, or 20 μM for 48 hours did not induce
decreased I-45-BTZ-R cell viability (Figure 2D). Although
combined treatment with AAF-CMK and bortezomib
significantly decreased cell viability as compared with
single agent treatment, cell viability remained very high
(>85%). These results suggest that TPPII did not compen-
sate for reduced proteasome activity in I-45-BTZ-R cells.
Figure 2 Expression of proteasome subunit proteins, proteasome activity, and ubiquitinated protein accumulation. A: I-45 and I-45-BTZ-R 
cells were treated with 40 nM bortezomib for 24, 48, or 72 hours. Expression of the proteasome subunits β1, β2, and β5 was analyzed by Western blot 
analysis. B: I-45 and I-45-BTZ-R cells were treated with 40 nM bortezomib for 8, 24, or 30 hours. Proteasome chymotrypsin-like activity was determined 
by measuring the release of the fluorophore 7-amido-4-methylcoumarin (AMC) from the substrate N-succinyl-Leu-Val-Tyr-7 (LLVY) amido-4-methyl-
coumarin. Values are the mean ± SD of three experiments. * p < 0.05 as compared to untreated I-45 cells. C: I-45 and I-45-BTZ-R cells were treated with 
40 nM bortezomib for 24, 48, or 72 hours. Expression of ubiquinated proteins were analyzed by Western blot analysis. D: I-45-BTZ-R cells were treated 
with 5, 10, or 20 μM AAF-CMK with or without 40 nM bortezomib for 48 hours. Cell viability was determined following treatment using the XTT assay. 
Control cells were treated with PBS and their viability was set as 100%. Values are the mean ± SD of triplicate assays from two experiments.
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Page 5 of 9Lack of cross-resistance to various anticancer drugs
The cellular multi-drug resistance proteins MDR1 (p-gly-
coprotein) and MRP1 are critical transmembrane efflux
pumps that transport various chemotherapeutic drugs
out of cells. Both I-45 and I-45-BTZ-R cells showed no
evidence of MDR1 or MRP1 by Western blot analysis
(data not shown) and both cell lines demonstrated similar
sensitivity to the chemotherapy drug cisplatin, which is
commonly used to treat patients with mesothelioma (Fig-
ure 3). We also tested the responses of both cell lines to
the chemotherapy drugs 5-fluorouracil and doxorubicin.
As was observed with cisplatin, both cell lines showed
similar sensitivity to treatment with 5-fluorouracil or
doxorubicin (data not shown), indicating there the
absence of cell line cross-resistance to common chemo-
therapy drugs.
Bortezomib does not induce ER stress and UPR in I-45-BTZ-
R cells
Recent studies demonstrated that bortezomib activates
ER stress and induces UPR in cancer cells [11,22]. Since
the mitochondrial chaperone protein Bip and the pro-
apoptotic transcriptional factor CHOP are markers of ER
stress, we evaluated Bip and CHOP protein expression in
I-45 and I-45-BTZ-R cells by Western blot analysis.
Results indicated that basal Bip expression was similar in
both cell lines. However, treatment with 40 nM borte-
zomib stimulated higher Bip and CHOP protein expres-
sion in I-45 cells but not in I-45-BTZ-R cells (Figure 4A).
These results indicated that bortezomib treatment did
not induce ER stress or UPR in I-45-BTZ-R cells. To
determine whether lethal concentrations of bortezomib
could induce ER stress and UPR, I-45-BTZ-R cells were
incubated with increasing concentrations of bortezomib
(40, 100, 200, and 400 nM). As is shown in Figure 4B,
bortezomib at 50 nM did not induce expression of either
Bip or CHOP. However, bortezomib at 100 to 400 nM
induced an increase in the expression of both Bip and
CHOP in parallel with an increase in apoptosis, as evi-
denced by increased cleavage of capase-3 and PARP.
Since CHOP is a pro-apoptotic transcriptional factor
during ER stress and UPR, we tested whether siRNA
knockdown of CHOP expression could protect I-45-
BTZ-R cells from bortezomib-induced cell death. Trans-
fection with 100 nM of CHOP siRNAs for 48 hours fol-
lowed by treatment with 200 nM bortezomib for an
additional 72 hours effectively reduced bortezomib-
mediated CHOP protein expression (Figure 5A). Knock-
down of CHOP gene expression also protected I-45-BTZ-
R cells from bortezomib-mediated apoptosis, as evi-
denced by a significant increase in cell viability from 53.9
± 5.4% to 72.3 ± 2.6% in cells treated with in control
siRNA versus CHOP-specific siRNA, respectively (Figure
Figure 4 ER stress activation and UPS induction. A: I-45 and I-45-
BTZ-R cells were treated with 40 nM bortezomib for 24, 48, or 72 hours. 
Expression of Bip, CHOP, or HSP27 was analyzed by Western blot anal-
ysis. B: I-45 and I-45-BTZ-R cells were treated with 50,100, 200, or 400 
nM bortezomib for 48 hours. Expression of Bip, CHOP, or noxa, and 
cleavage of caspase-3 and PARP was analyzed by Western blot analysis.
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Page 6 of 95B). In addition, our data also demonstrated that siRNA-
mediated knockdown of CHOP gene expression also par-
tially protected parental I-45 cells from bortezomib-
induced cell death (data not shown).
Bortezomib induces noxa protein expression in I-45 cells 
but not in I-45-BTZ-R cells
To better understand the molecular mechanisms under-
lying bortezomib resistance in I-45-BTZ-R cells, we
examined BCl-2 family member protein expression by
Western blot analysis. Results indicated that several Bcl-2
family proteins showed altered protein expression follow-
ing bortezomib treatment (Figure 6). First, Bcl-xL protein
expression increased slightly from 24 to 72 hours after
treatment with 40 nM bortezomib in both of the cell
lines, which may not account for bortezomib resistance in
I-45-BTZ-R cells. Second, bortezomib treatment
increased expression of the anti-apoptotic protein Mcl-
1L in I-45 cells approximately 100% at 24, 48, or 72 hours,
while expression of the pro-apoptotic protein Mcl-1S was
increased approximately 150% at 24 hours, but then
decreased at 48 and 72 hours, Pro-apoptotic Mcl-1S is
reported to be a BH3 domain-only protein capable of
dimerizing with Mcl-1L, thus reducing mcl-1L anti-apop-
totic function [23]. Different results were observed in in
I-45-BTZ-R cells, where bortezomib treatment slightly
increased Mcl-1L expression over time, but no change in
Mcl-1S expression was detected.
Strong expression of the noxa protein was also detected
in I-45 cells after treatment with bortezomib, while noxa
expression was barely detectable in I-45-BTZ-R cells sub-
jected to the same treatment (Figure 6). Impressively,
bortezomib at 100 to 400 nM also induced strong noxa
expression in I-45-BTZ-R cells (Figure 4B), suggesting
that noxa expression was correlated with bortezomib-
induced cell death.
In addition, 40 nM bortezomib treatment induced
strong p53 protein accumulation in parental I-45 cells,
but only week p53 protein accumulation was observed in
I-45-BTZ-R cells following bortezomib exposure (Figure
6).
Discussion
In the present study, we developed a bortezomib-resis-
tant cell line (I-45-BTZ-R) from a bortezomib-sensitive
mesothelioma cell line (I-45). I-45-BTZ-R cells showed
no cross-resistance with the common chemotherapeutic
drugs cisplatin, 5-fluorouracil, and doxorubicin. More-
over, we observed that the bortezomib-adapted I-45-
BTZ-R cells exhibited decreased growth kinemics as
Figure 6 Bcl-2 family protein expression following the borte-
zomib treatment. I-45 and I-45-BTZ-R cells were treated with 40 nM 
bortezomib for 24, 48, or 72 hours. Expression of Bcl-xL, Mcl-1, Bax, 
noxa, or p53 was determined by Western blot analysis.
I-45                       I-45-BTZ-R
0     24     48     72     0      24     48     72    hours
Bcl-xL
Mcl-1L
Mcl-1S
Bax
noxa
Ub p53
-actin
p53
-
Figure 5 Effects of siRNA inhibition of CHOP expression on borte-
zomib-induced changes in I-45-BTZ-R cell viability. A: I-45-BTZ-R 
cells were transfected with 100 nM CHOP-specific siRNA or control siR-
NA. After 48 hours, cells were treated with 200 nM bortezomib for an 
additional 48 hours, and then CHOP protein expression was deter-
mined by Western blot analysis. B: I-45-BTZ-R cells were treated as de-
scribed above, and then cell viability was determined using the XTT 
assay. Values are the mean ± SD of three experiments. * p < 0.05 as 
compared to treatment with bortezomib following transfection with 
control siRNA.
control siRNA      - +       - - +      -
CHOP siRNA        - - +      - - + 
no treatment      bortezomib
A
CHOP
1.2
-actin
0 2
0.4
0.6
0.8
1
C
el
l v
ia
bi
lit
yB *
0
.
control siRNA      +       - +       -
CHOP siRNA       - +                   - + 
no treatment                bortezomib
Zhang et al. Molecular Cancer 2010, 9:110
http://www.molecular-cancer.com/content/9/1/110
Page 7 of 9compared to the parental I-45 cells. We also found that I-
45-BTZ-R cells did not over express the proteasome sub-
unit PSMB5 as compared with the parental I-45 cells. In
addition, 40 nM bortezomib induced similar inhibition of
proteasome activity in the bortezomib-adapted cells and
the parental I-45 cells, but significantly reduced accumu-
lation of ubiquitinated protein accumulation. Further
studies revealed that relatively low doses of bortezomib
did not induce UPR in the bortezomib-adapted cells,
while higher doses induced UPR with concomitant cell
death, as evidenced by higher protein expression of the
mitochondrial chaperone Bip and the ER stress-related
pro-apoptotic gene CHOP. Bortezomib treatment of I-45-
BTZ-R cells also failed to induce the accumulation of the
pro-apoptotic genes p53, Mcl-1S, and noxa. These results
suggest that evading UPR together with reduced induc-
tion of pro-apoptotic gene expression accounts for borte-
zomib resistance in these bortezomib-adapted
mesothelioma cells.
Bortezomib is a reversible proteasome inhibitor that
primarily targets the PSMB5 subunit, which is responsi-
ble for 26S proteasome chymotrypsin activity. Several
research groups have recently developed bortezomib-
resistant cells representing different type of cancer,
including acute myeloid leukemia, lymphoma, and MM
[16-19]. Most of the reported bortezomib-adapted cells
have shown higher PSMB5 RNA and protein expression
as compared to the respective parental bortezomib-sensi-
tive cells. A missense point mutation has been reported
in a highly conserved PSMB5 bortezomib-binding pocket
and that siRNA-mediated reduction of PSMB5 expres-
sion restored bortezomib sensitivity in the bortezomib-
resistant cell line [18]. In line with higher PSMB5 expres-
sion, most reported bortezomib-adapted cells showed
increased proteasome activity as compared to their
respective parental cell lines [16-19]. This increased
activity has been used as a basis for explaining increased
cell survival following a lethal challenge with proteasome
inhibition. In the present study, over expression of pro-
teasome subunit PSMB5 was not observed. We also did
not find any mutations by DNA sequencing in the coding
region of PSMB5 in both of the cell lines (data not
shown). Accordingly, the bortezomib-adapted cells and I-
45 cells showed the same degree of bortezomib-induced
proteasome inhibition. I-45-BTZ-R cells showed much
less accumulation of ubiquitinated proteins following
bortezomib treatment. There are two possible explana-
tions for this observation. First, an alternate protease
pathway may compensate for reduced proteasome func-
tion. For example, in lymphoma, continuous inhibition of
proteasome activity selected for proteasome inhibitor-
resistant cells with lower proteasome activity, but higher
expression of TPPII, which effectively replaced certain
proteasome functions [20,21]. However, TPPII was not
upregulated in I-45-BTZ-R cells (data not shown) and
inhibition of TPPII activity using the specific inhibitor
AAF-cmk had very little effect on the sensitivity of I-45-
BTZ-R cells to bortezomib (Figure 2D). However, we
could not exclude the possibility that the activity of other,
as-yet unidentified proteases compensated for reduced
proteasome function in I-45-BTZ-R cells. Second, the
slower growth of I-45-BTZ-R cells may have induced a
general decrease in protein synthesis, resulting in a
reduction in the number of ubiquitinated proteins. This
possibility may also partially explain our observation that
relatively low concentrations of bortezomib did not
induce ER stress and UPR in I-45-BTZ-R cells.
The ER is a eukaryotic organelle critical to the produc-
tion and modification of one third of all cellular proteins.
In the ER lumen, excessive accumulation of misfolded or
oxidized proteins induced by ER stress leads to induction
of the UPR, a protective mechanism that initially restores
the luminal folding capacity of the ER, but will ultimately
trigger cell death if the protective mechanism is over-
whelmed. During ER stress, increased concentrations of
protein chaperones, particularly Bip, can limit protein
aggregation inside the ER and inhibit general protein syn-
thesis in order to reduce the ER-Golgi network workload
and the cellular damage induced by ER stress [22,24,25].
CHOP, another protein marker of ER stress, functions to
mediate the execution of programmed cell death
[22,24,25]. It has been reported that bortezomib induces
apoptosis in MM [11] and head and neck squamous car-
cinoma cells [26] by activating ER stress concurrent with
upregulation of Bip and CHOP. In the present study, we
observed upregulation of Bip and CHOP in the borte-
zomib-sensitive cell line I-45 following bortezomib treat-
ment, indicating bortezomib was able to induce ER stress
in this mesothelioma cell line. However, low doses of
bortezomib did not induce ER stress and apoptosis in the
bortezomib-resistant cell line I-45-BTZ-R. Since protea-
some inhibition resulting in the accumulation of ubiquit-
inated proteins is thought to induce ER stress and the
UPR, reduced accumulation of ubiquitinated proteins in
I-45-BTZ-R cells may have prevented ER stress induction
and UPR-mediated cell death. Reduced accumulation of
ubiquitinated proteins may have also decreased the stabi-
lization of the pro-apoptotic proteins p53, Mcl-1S, and
noxa in I-45-BTZ-R cells, thus further limiting borte-
zomib-induced apoptosis.
In agreement with the results of the present study, most
other reported bortezomib-adapted cells did not exhibit
much cross-resistance to most chemotherapeutic drugs
[16,18]. These observations indicate that cancer cell resis-
tance to bortezomib treatment can be overcome by most
other therapies. Therefore, even though combination
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tics does not show synergistic efficacy, such therapeutic
approaches may still benefit patients through a reduction
in the development of bortezomib resistance. Although
expression of the multi-drug resistance proteins MDR1
and MRP1 was not detected in either I-45 or I-45-BTZ-R
cell lines, we demonstrated that bortezomib can enter I-
45-BTZ-R cells and access to the proteasome complex
through direct assessment of proteasome activity. I-45-
BTZ-R cells, which exhibit an approximately 30%
decrease in basal proteasome activity as compared to I-45
cells, showed the same degree of proteasome inhibition
following bortezomib treatment at doses that readily
killed I-45-cells but spared I-45-BTZ-R cells.
Conclusions
The present study provides evidence supporting a new
mechanism of bortezomib resistance that is independent
of proteasome subunit PSMB5 expression and protea-
some activity. In I-45-BTZ-R cells, reduced accumulation
of ubiquitinated proteins prevents bortezomib induction
of ER stress and the UPR and reduces the stabilization of
the pro-apoptotic proteins p53, Mcl-1S, and noxa. These
changes may account for bortezomib resistance in this
cell line.
Methods
Cell Culture and Reagents
The human sarcomatoid type mesothelioma cell line I-45
expressing wild type p53 was kindly provided by Dr. J.
Testa (Fox Chase Institute, Philadelphia, PA). Cells were
grown in RPMI 1640 medium supplemented with 10%
fetal bovine serum, glutamine, and antibiotics. Cells were
cultured at 37°C in a humidified incubator containing a
5% CO2 atmosphere. Bortezomib was kindly provided by
Millennium: The Takeda Oncology Company (Cam-
bridge, MA) and was dissolved in phosphate buffered
saline (PBS) to make a stock concentration of 100 μM.
Cell Viability Assay
Cells were seeded at a density of 5000 cells/well in 96-well
plates one day before exposure to various treatments. Fol-
lowing treatment, cell viability was determined using an
XTT cell viability assay (Cell Proliferation Kit II, Roche
Molecular Biochemicals, Indianapolis, IN) according to
the manufacturer's protocol and as previously described
[27].
Cell Growth Assay
Cells were seeded in 20 cm cell culture dishes at a density
of 1 × 106 cells per dish. Cells were trypsinized at days 2,
4, 6, or 8 and stained with trypan blue. Viable cells were
counted under a microscope using a hemocytometer.
Western Blot Analysis
Western blot analysis was performed as described previ-
ously [27]. Rabbit polyclonal antibodies against PARP,
caspase-3, Bcl-xL, Bax, Bip, HSP27, or CHOP were pur-
chased from Cell Signaling (Beverly, MA). Rabbit poly-
clonal anti-human p53 and Mcl-1 antibodies were
provided by Santa Cruz Biotechnology (Santa Cruz, CA).
A mouse monoclonal anti-human noxa antibody was
purchased from Calbiochem (San Diego, CA). Mouse
monoclonal antibodies against human 20S proteasome
subunits β1, β2, β5 and anti-ubiquitin (FK2H) antibodies
were obtained from Biomol (Plymouth Meeting, PA).
Small Interfering RNA Transfection
CHOP expression was silenced using a pool of four small
interfering RNAs (siRNAs) directed against CHOP
mRNA (Dharmacon, Lafayette, CO). Cells were trans-
fected with 100 nM of CHOP-specific siRNA or siCON-
TROL Non-Targeting Pool siRNAs (Dharmacon) using
the transfection reagent Dharma FECT 1 (Dharmacon)
according to the manufacturer's protocol. Cells were cul-
tured for 48 hours, and then treated simultaneously with
bortezomib for an additional 72 hours.
Flow Cytometry
Cells were trypsinized, washed once with cold PBS, and
then fixed with 70% ethanol overnight at 4°C. Fixed cells
were suspended in PBS containing 25 μg/mL propidium
iodide (Roche Diagnostics, Indianapolis, IN) and 10 μg/
mL RNase A (Sigma-Aldrich, St. Louis, MO) at 3°C for 30
minutes. Flow cytometry analysis for cell cycle distribu-
tion and determination of the sub-G1 apoptotic cell pop-
ulation was performed as previously described [27].
Proteasome chymotrypsin-like activity assay
Cells treated with bortezomib and untreated control cells
were lysed in 20 mM Tris-HCl buffer (pH7.6) by repeated
freezing in liquid nitrogen and thawing in a 37°C water
bath. Cell lysate chymotrypsin-like activity was deter-
mined by measuring the release of the fluorophore 7-
amido-4-methylcoumarin (AMC) from 10 μM of the sub-
strate N-succinyl-Leu-Val-Tyr-7 (LLVY) amido-4-meth-
ylcoumarin (Sigma-Aldrich). Fluorescence was measured
on a Flexstation microplate fluorometer (Molecular
Devices, Sunnyvale, CA, USA) at excitation/emission
wavelengths of 380/440 nm.
Statistical Analysis
Differences among treatment groups were assessed by
analysis of variance using PRISM 4 software. P values of =
0.05 were regarded as significant.
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